Who Paid My Doc
Matthew Trefz
Pediatric Cardiology Fargo, ND Medical Doctor
NPI 1376735035 CMS profile 1143097
801 Broadway N, Fargo, ND 58102
General payments
$72
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Matthew Trefz of Fargo, ND is reported in the CMS Open Payments database as having received $72 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 24th percentile of Pediatric Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $72 | 2 |
Beside peers
- Matthew Trefz
- Pediatric Cardiology median
- Middle half of Pediatric Cardiology
- National median
In program year 2025, general payments to Matthew Trefz were reported at $72. Among 1,168 Pediatric Cardiology profiles paid that year, the median was $146 and the middle half received between $47 and $670.
Show as a table
| Year | Matthew Trefz | Pediatric Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $124 | $35–$516 | $163 |
| 2020 | $0 | $70 | $23–$326 | $114 |
| 2021 | $0 | $112 | $27–$445 | $132 |
| 2022 | $0 | $129 | $36–$680 | $149 |
| 2023 | $0 | $149 | $38–$826 | $160 |
| 2024 | $0 | $131 | $37–$652 | $164 |
| 2025 | $72 | $146 | $47–$670 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
56
Drug cost
$182
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Metoprolol Tartrate | Generic | 16 | $88 | |
| Furosemide | Generic | 14 | $51 | |
| Metoprolol Succinate | Generic | 12 | $31 | |
| Lisinopril | Generic | 14 | $12 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$2,299
Medicare patients
27
Services billed
111
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Ischemic heart disease | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pediatric Cardiology in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.